咖啡因作为帕金森病症状性治疗(Café-PD):一项随机试验
主要研究问题为6个月时客观运动评分(MDS-UPDRS-III)是否不同。结果显示咖啡因耐受良好,但运动症状无改善,且与安慰剂相比差异为-0.48分(95%CI -3.21至2.25),次要结局亦无显著差异,认知测试评分稍差。
要点
- 咖啡因200mg每日两次未改善帕金森病患者的运动症状(MDS-UPDRS-III)。
- 咖啡因耐受良好,副作用与安慰剂相似,但轻微增加异动症并可能轻微恶化认知。
- 流行病学中咖啡因与较低帕金森病风险的关联可能并非通过症状性效应解释。
核心结论
- 咖啡因未对帕金森病患者的运动表现提供临床重要改善(I级证据)。
主要发现
- 主要结局MDS-UPDRS-III评分组间差异为-0.48分(95%CI -3.21至2.25),无显著改善。
- 次要结局中运动症状(MDS-UPDRS-II)任何时间点均无变化,生活质量无差异。
- 咖啡因组嗜睡在前6个月轻微改善但随时间减弱,异动症轻微增加(MDS-UPDRS-4.1+4.2评分高0.25分)。
- 认知测试评分较安慰剂组平均差0.66分(95%CI 0.01至1.32),即更差。
关键数值与推荐
- 主要结局为6个月时MDS-UPDRS-III评分变化。
- 咖啡因剂量为200mg每日两次,安慰剂为匹配胶囊。
临床怎么用
- 不推荐使用咖啡因作为帕金森病运动症状的症状性治疗。
- 处方咖啡因时需注意可能轻微增加异动症和认知评分下降的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess effects of caffeine on Parkinson disease (PD). METHODS: In this multicenter parallel-group controlled trial, patients with PD with 1-8 years disease duration, Hoehn & Yahr stages I-III, on stable symptomatic therapy were randomized to caffeine 200 mg BID vs matching placebo capsules for 6-18 months. The primary research question was whether objective motor scores would differ at 6 months (Movement Disorder Society-sponsored Unified Parkinson's Disease Rating Scale [MDS-UPDRS]-III, Class I evidence). Secondary outcomes included safety and tolerability, motor symptoms (MDS-UPDRS-II), motor fluctuations, sleep, nonmotor symptoms (MDS-UPDRS-I), cognition (Montreal Cognitive Assessment), and quality of life. RESULTS: Sixty patients received caffeine and 61 placebo. Caffeine was well-tolerated with similar prevalence of side effects as placebo. There was no improvement in motor parkinsonism (the primary outcome) with caffeine treatment compared to placebo (difference between groups -0.48 [95% confidence interval -3.21 to 2.25] points on MDS-UPDRS-III). Similarly, on secondary outcomes, there was no change in motor signs or motor symptoms (MDS-UPDRS-II) at any time point, and no difference on quality of life. There was a slight improvement in somnolence over the first 6 months, which attenuated over time. There was a slight increase in dyskinesia with caffeine (MDS-UPDRS-4.1+4.2 = 0.25 points higher), and caffeine was associated with worse cognitive testing scores (average Montreal Cognitive Assessment = 0.66 [0.01, 1.32] worse than placebo). CONCLUSION: Caffeine did not provide clinically important improvement of motor manifestations of PD (Class I evidence). Epidemiologic links between caffeine and lower PD risk do not appear to be explained by symptomatic effects. CLINICALTRIALSGOV IDENTIFIER: NCT01738178. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with PD, caffeine does not significantly improve motor manifestations.
引用
- Postuma RB, Anang J, Pelletier A, et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial. Neurology. 2017. PMID: 28954882. doi:10.1212/WNL.0000000000004568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。